Search
Clinician Ordering Portal
Frequently Asked Questions
TissueCypher provides a risk score and probability of development of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) within five years. In a recent study by the Mayo Clinic, TissueCypher was shown to independently predict increased risk of progression to HGD/EAC and was also shown to be a stronger predictor of progression than other traditional risk factors like age, sex, segment length, and even expert pathology. Multiple published studies have shown that TissueCypher has a higher positive predictive value than these traditional risk factors, e.g., patients who receive a TissueCypher high-risk score progress at a higher rate than patients with confirmed low-grade dysplasia.
Please call our customer service staff at 866-788-9007 or email.